Compare TWO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWO | XERS |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | 486 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | TWO | XERS |
|---|---|---|
| Price | $12.52 | $6.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $12.56 | $10.83 |
| AVG Volume (30 Days) | ★ 2.4M | 1.6M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.77% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | N/A | $22.86 |
| P/E Ratio | ★ N/A | $638.48 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $8.84 | $4.30 |
| 52 Week High | $14.17 | $10.08 |
| Indicator | TWO | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 66.49 | 49.57 |
| Support Level | $9.75 | $5.79 |
| Resistance Level | $12.70 | $6.41 |
| Average True Range (ATR) | 0.13 | 0.32 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 56.90 | 28.51 |
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, residential mortgage loans, mortgage servicing rights, and commercial real estate. The majority of its investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. The company derives revenues mainly from its MSR and Agency RMBS portfolio, including servicing fee income, float income, and interest income, as well as mortgage loan origination activities established to support the MSR portfolio. Its investment portfolio is subject to market risks, mainly interest rate, basis, and prepayment risk. The majority of income is generated by available-for-sale securities.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.